Compare

Novartis/$NVS

1D1W1M3M6MYTD1Y5YMAX

About Novartis

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Ticker
$NVS
Sector
Health
Primary listing
NYSE
Employees
75,267
Headquarters
Basel, Switzerland
Website
www.novartis.com

Novartis Metrics

BasicAdvanced
$293B
29.97
$5.23
-
$3.08
1.96%

What the Analysts think about Novartis

Analyst ratings (Buy, Hold, Sell) for Novartis stock.
Analyst projections of the future price of Novartis stock.

Bulls say / Bears say

Novartis returned to sales growth in Q2 as Kisqali, Kesimpta and Scemblix grew 43%, 32% and 89% respectively at constant currencies. That momentum supports the company’s reaffirmed 2026 guidance. (Novartis)
The FDA’s expanded Pluvicto approval brings the treatment into an earlier prostate-cancer setting, nearly doubling the number of patients who may be eligible. In the pivotal trial, it reduced the risk of progression or death by 28% against standard care. (Novartis)
Remibrutinib succeeded in two late-stage trials for relapsing multiple sclerosis, outperforming an established treatment in reducing relapses. Novartis plans to seek regulatory approval, giving the drug potential to grow beyond its existing use in chronic hives. (Reuters, SEC)
Entresto’s US sales have fallen sharply since generic competition began, and European exclusivity is due to expire in November 2026. Novartis expects only low-single-digit sales growth and a low-single-digit decline in core operating income this year. (Reuters, Novartis)
Two hoped-for pipeline drivers have stumbled: pelacarsen failed to reduce cardiovascular events, while del-desiran missed its main goal in a late-stage trial. The setbacks weaken the case that new medicines will readily replace sales lost to generics. (Reuters, Reuters)
The Q2 profit beat may not be easy to repeat: one-off benefits are expected to reverse as research and launch spending rises in the second half. That could deepen pressure on earnings while core operating income is forecast to decline this year. (Reuters, Novartis)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.

Novartis Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Novartis Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Novartis News

AllArticlesVideos

What Novartis (NVS) Said on Its Q3 Earnings Call

MarketBeat20 hours ago

Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit

Benzinga1 day ago

Novartis Raises Guidance Despite Trial Setbacks Hitting Profit

WSJ1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.